Hiroaki Okuyama
Overview
Explore the profile of Hiroaki Okuyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
2773
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mizuno H, Yamashita W, Okuyama H, Takase N, Tohyama N, Shimizu H, et al.
Phys Med
. 2021 Jul;
88:91-97.
PMID: 34214838
Purpose: We experimentally determined the radiophotoluminescent glass dosimeter (RPLD) dose responses for TomoTherapy, CyberKnife, and flattening-filter-free (FFF) linear accelerator (linac) outputs for dosimetry audits in Japan. Methods: A custom-made solid...
2.
Onuma K, Sato Y, Okuyama H, Uematsu H, Homma K, Ohue M, et al.
J Pathol
. 2021 Jun;
255(1):84-94.
PMID: 34156098
Micropapillary carcinoma (MPC) is a morphologically distinctive form of carcinoma, composed of small nests of cancer cells surrounded by lacunar spaces. Invasive MPC is associated with poor prognosis. The nests...
3.
Kondo J, Ekawa T, Endo H, Yamazaki K, Tanaka N, Kukita Y, et al.
Cancer Sci
. 2018 Oct;
110(1):345-355.
PMID: 30343529
Patient-derived cancer organoid culture is an important live material that reflects clinical heterogeneity. However, the limited amount of organoids available for each case as well as the considerable amount of...
4.
Piulats J, Kondo J, Endo H, Ono H, Hagihara T, Okuyama H, et al.
Oncotarget
. 2018 Apr;
9(22):15968-15983.
PMID: 29662620
Individual and small clusters of cancer cells may detach from the edges of a main tumor and invade vessels, which can act as the origin of metastasis; however, the mechanism...
5.
Yoshida T, Okuyama H, Endo H, Inoue M
Methods Mol Biol
. 2017 Sep;
1655:145-153.
PMID: 28889384
Increasingly, it has been recognized that studying cancer samples from individual patients is important for the development of effective therapeutic strategies and in endeavors to overcome therapy resistance. Primary cultures...
6.
Tashiro T, Okuyama H, Endo H, Kawada K, Ashida Y, Ohue M, et al.
PLoS One
. 2017 Mar;
12(3):e0174151.
PMID: 28301591
In clinic, cetuximab, an anti-EGFR antibody, improves treatment outcomes in colorectal cancer (CRC). KRAS-mutant CRC is generally resistant to cetuximab, although difference of the sensitivity among KRAS-mutants has not been...
7.
Hiraide T, Ikegami K, Sakaguchi T, Morita Y, Hayasaka T, Masaki N, et al.
Sci Rep
. 2016 Jul;
6:29935.
PMID: 27435310
Accumulating evidence indicates that cancer cells show specific alterations in phospholipid metabolism that contribute to tumour progression in several types of cancer, including colorectal cancer. Questions still remain as to...
8.
Sato Y, Tateno H, Adachi J, Okuyama H, Endo H, Tomonaga T, et al.
Sci Rep
. 2016 Jun;
6:26575.
PMID: 27241769
No abstract available.
9.
Sato Y, Tateno H, Adachi J, Okuyama H, Endo H, Tomonaga T, et al.
Sci Rep
. 2016 Apr;
6:24823.
PMID: 27098764
Spheroids cultured directly from tumours can better reflect in vivo tumour characteristics than two-dimensional monolayer culture or three-dimensional culture of established cell lines. In this study, we generated antibodies by...
10.
Okuyama H, Kondo J, Sato Y, Endo H, Nakajima A, Piulats J, et al.
Am J Pathol
. 2016 Feb;
186(4):899-911.
PMID: 26878211
Intestinal epithelial cells possess apical-basal polarity, which governs the exchange of nutrients and waste. Perturbation of cell polarity appears to be a general feature of cancers, although most colorectal cancers...